The reason you have not received any referrals is because the Trump administration has already delayed the implementation of these penalties not once, not twice, not three times, but four separate times since 2017.

So why on Earth would this be the time to reduce capital standards for these too-big-to-fail banks?

These findings led Congress to include a provision in the Affordable Care Act to crackdown on this behavior.

In order for the 340B Program to work, the ceiling price calculations need to be done correctly, and there need to be consequences when drug companies break the law and deliberately overcharge for these drugs.

The GAO raised concerns that the 340B Program, quote, 'Primarily relies on self-policing; that is, participants ensuring their own compliance with program requirements.'

The 340B Program has one basic requirement, that drug companies must provide discounted medications to hospitals and clinics caring for the most vulnerable patients: children with cancer, the uninsured, the underinsured, people with HIV…

If the President is truly worried about the connection between high drug prices and the 340B Program, he could start by implementing the law that Congress wrote to actually stop drug companies from cheating on their discounts.

I want to start by thanking my colleague from Rhode Island for both his powerful analysis of the influence of money on the selection of our judicial nominees and also for his point about the blue slip and the implications of what this…

I think that is great. But we cannot mistake this market for a competitive market.

The answer is, after a hundred years, zero.

So my view on this is that when it comes to keeping prices low for consumers, nothing beats a competitive market.

I see an industry that is doing everything it can to throw sand in the gears of the insulin market.